Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Search
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Light Meal
Take a look through our tempting lighter bites from Taking Cancer on Through Flavour here.
Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim
Explore our advanced capabilities in antibody production, and learn about the unique features of monoclonal & polyclonal antibodies.
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Stroke Prevention in AF
Stroke Prevention in AF
About Us
About us
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
The big, the bold, and the few
In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Leticia develops product medical strategies
Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Laura loves her diverse career
Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Exploring beyond boundaries for innovation in animal health
Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
FDA-Fast-Track-chronic-kidney-disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction